HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sunscreen claims, OTC labeling

This article was originally published in The Rose Sheet

Executive Summary

FDA's latest public estimate of when it will issue a proposed rule on sunscreen UVA/UVB claims is April 2003, according to the agency's 1unified agenda, appearing in the May 13 Federal Register. The target date is beyond previous indications from the agency that amendment to sunscreen final monograph would be published before the end of 2002. Agenda targets December for release of proposal providing flexibility for labeling of small one- or two-dose "convenience" size OTC drugs. While rulemaking proceeds, such products are excused from complying with OTC drug labeling requirements (2"The Rose Sheet" April 8, 2002, p. 10). Current OTC review agenda is more abbreviated than usual; FDA decided to list only those actions expected to be completed within next 12 months, the agency said...

You may also be interested in...

OTC review agenda

Target date for completing notice of proposed rulemaking for sunscreen UVA/UVB products pushed back to August in FDA's 1unified agenda published in the Federal Register Dec. 9. Most recent public estimate for completion was April (2"The Rose Sheet" May 20, 2002, In Brief). Proposal for providing labeling flexibility for "convenience" size OTC drugs targeted for March, while antiperspirant products final monograph is expected to be completed in April, agency adds. Final action on skin protectant products anticipated in April with NPRM for astringent scheduled to follow in August...

OTC Labeling Compliance Date Delayed For “Convenience-Size” Items

"Convenience-size" OTC drugs will not be required to meet "Drug Facts" reg compliance dates until FDA publishes either a final rule or further notice on the labeling of such products

On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements

So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts